1.76
0.00%
Close of 9 Nov 2026, in RUB
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Farmsintez PAO
Its shares trade on MOEX under the ticker LIFE.ME. It has been listed since 24 November 2010. In the fiscal year to 31 December 2025, it reported revenue of RUB 155.9m and a net loss of RUB 253.9m. At that date it held total assets of RUB 2.73bn and shareholders' equity of RUB 1.81bn.
Pharmsynthez PJSC engages in the research, development, manufacture, and distribution of pharmaceuticals. The firm focuses on the medical research, development and manufacture of drugs ingredients used in oncology, gynecology, tuberculosis therapy and others. In addition, Farmsintez OAO offers chemical research services, chemical technology development and quality control services. The firm sells its products domestically, as well as abroad, including the Commonwealth of Independence State (CIS) countries. The company has two wholly owned subsidiaries located in Moscow and Tallin, Estonia. As of May 21, 2011, the Company’s major shareholder was EphaG AS with a stake of 69.23%. In April 2013, the Company acquired the pharmacies of Guardum Pharmaceuticals in the U.S. state of Florida.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 24 Nov 2010
- Website
- pharmsynthez.com ↗
Leadership
Pay as last reported
- Dr. Dmitry GenkinChairman of the Board
- Mr. Kirill MayorovGeneral Director (CEO)
- Mr. Sergey BezhanovDirector
- Mr. Steve GorelikDirector
- Mr. Indrek KaselaDirector
- Mr. Roman KnyazevDirector
- Mr. Dmitry KolosovDirector
- Mr. Petr KruglyakovDirector
- Ms. Olga ShpichkoDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pharmsynthez PJSC focuses on oncology and tuberculosis drug development in the pharmaceutical sector.
- The company operates two wholly owned subsidiaries in Moscow and Tallinn, Estonia, enhancing regional presence.
- EphaG AS holds a 69.23% stake as the major shareholder, ensuring strong ownership support.
Weaknesses
- Pharmsynthez PAO relies on a single major shareholder EphaG AS for significant ownership control.
- The company's product focus on specific medical areas may limit broader market diversification.
- Acquisition of Guardum Pharmaceuticals' U.S. pharmacies in 2013 may pose integration challenges.
Opportunities
- Expansion into Commonwealth of Independent States (CIS) countries offers growth potential for pharmaceutical distribution.
- The U.S. Florida pharmacy acquisition provides a foothold in the North American market.
- Increasing demand for oncology and tuberculosis treatments presents new market opportunities.
Threats
- Dependence on a single shareholder EphaG AS could lead to governance risks.
- Competition in the pharmaceutical industry may intensify with new entrants.
- Regulatory changes in CIS countries could impact distribution and operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.